These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7963519)

  • 1. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
    Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
    J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
    Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
    Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
    Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
    J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
    D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
    J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases.
    D'Addario M; Ahmad A; Morgan A; Menezes J
    J Mol Biol; 2000 May; 298(5):765-78. PubMed ID: 10801347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
    Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
    Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes.
    Barel M; Fiandino A; Delcayre AX; Lyamani F; Frade R
    J Immunol; 1988 Sep; 141(5):1590-5. PubMed ID: 2842398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma.
    Jenson HB; Montalvo EA; McClain KL; Ench Y; Heard P; Christy BA; Dewalt-Hagan PJ; Moyer MP
    J Med Virol; 1999 Jan; 57(1):36-46. PubMed ID: 9890420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
    Chodosh J; Gan Yj; Holder VP; Sixbey JW
    Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21.
    Gill MB; Roecklein-Canfield J; Sage DR; Zambela-Soediono M; Longtine N; Uknis M; Fingeroth JD
    J Cell Sci; 2004 Jun; 117(Pt 13):2709-20. PubMed ID: 15138285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
    Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
    J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).
    Siaw MF; Nemerow GR; Cooper NR
    J Immunol; 1986 Jun; 136(11):4146-51. PubMed ID: 3009616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
    Mold C; Cooper NR; Nemerow GR
    J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes.
    López R; Urquiza M; Patino H; Suárez J; Reyes C; Patarroyo MA; Patarroyo ME
    Biochimie; 2005 Nov; 87(11):985-92. PubMed ID: 15927339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo.
    Servat E; Ro BW; Cayatte C; Gemmell L; Barton C; Rao E; Lin R; Zuo F; Woo JC; Hayes GM
    Vaccine; 2015 Nov; 33(48):6771-7. PubMed ID: 26485517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
    Smith NA; Coleman CB; Gewurz BE; Rochford R
    J Virol; 2020 May; 94(11):. PubMed ID: 32238579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.